P-6380
American Journal of Hematology | 2026
Phase II study of posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-mismatched unrelated donor reduced intensity transplantation: Results from the ACCESS trial expansion cohort.
Schaffer BC, Al Malki MM, Jimenez AMJ, Stanek J, Bo-Subait S, Logan BR, Kou J, Leckrone E, Stefanski HE, Spellman SR, Malmberg C, Askar M, Cusatis R, Modi D, Khimani F, Hamadani M, Maiers M, Cook R, Ballen K, Bolaños-Meade J, Rao U, Milner J, Abboud R, Jamieson K, Carrum G, Dholaria B, Hogan WJ, Reshef R, Kosuri S, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Auletta JJ, Shaw BE, Devine SM, Gooptu M
PubMed
PMID: 42674730
CIBMTR Study #: CIBMTR_NA